2021 IPO

Bolt Biotherapeutics Stock

Bolt Therapeutics plans to develop a novel format for T-cell mediated anti-tumour therapy.

Sign up today and learn more about Bolt Biotherapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Bolt Biotherapeutics Stock

Bolt Therapeutics plans to develop a novel format for T-cell mediated anti-tumour therapy.

Funding History

March 2015$600K
September 2016$10.0M
August 2018$19.4M
February 2019$54.0M

Management

President and CEO

Reiner Laus

Chief Business Officer

Grant Yonehiro

Chief Executive Officer and Director

CP Liu

Founder

Edgar Engleman

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo